Dermata Therapeutics Inc
$ 1.34
-1.47%
20 Apr - close price
- Market Cap 5,470,100 USD
- Current Price $ 1.34
- High / Low $ 1.40 / 1.32
- Stock P/E N/A
- Book Value 2.34
- EPS -8.16
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.85 %
- ROE -1.94 %
- 52 Week High 9.90
- 52 Week Low 1.10
About
Dermata Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative therapies for dermatological conditions. With its lead asset, DMT310, the company employs a novel delivery system designed to enhance treatment efficacy for acne and other skin disorders, thereby addressing significant unmet medical needs within the dermatology market. Dermata's strategically curated pipeline and proprietary technologies highlight its commitment to advancing skin health and improving patient outcomes. As the company progresses through its clinical trials, it is well-positioned to become a leader in the dermatological sector, poised to make a substantial impact on the treatment landscape for skin-related issues.
Analyst Target Price
$4.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-27 | 2025-11-14 | 2025-08-13 | 2025-05-07 | 2025-03-17 | 2024-11-15 | 2024-08-15 | 2024-05-15 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -1.52 | -1.65 | -2.67 | -1.2515 | -0.92 | -20.4 | -4.18 | -7.05 | -0.21 | -0.54 | -0.63 | -2.27 |
| Estimated EPS | -1.54 | -0.32 | -0.44 | -0.45 | -0.32 | -26.4 | -3.79 | -5.4 | -0.78 | -0.63 | -0.92 | -2.65 |
| Surprise | 0.02 | -1.33 | -2.23 | -0.8015 | -0.6 | 6 | -0.39 | -1.65 | 0.57 | 0.09 | 0.29 | 0.38 |
| Surprise Percentage | 1.2987% | -415.625% | -506.8182% | -178.1111% | -187.5% | 22.7273% | -10.2902% | -30.5556% | 73.0769% | 14.2857% | 31.5217% | 14.3396% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DRMA
2026-04-17 21:39:13
Dermata Therapeutics (NASDAQ: DRMA) is seeking stockholder approval for seven proposals at its virtual 2026 annual meeting on May 27, 2026. Key proposals include electing three Class II directors, ratifying CBIZ CPAs P.C. as independent auditor, approving the issuance of common shares underlying warrants that could exceed 20% of outstanding common stock for Nasdaq compliance, repricing warrants for up to 120,734 shares, and increasing the 2021 Omnibus Equity Incentive Plan reserve to 402,214 shares. The company reports a neutral filing impact and sentiment, noting that the warrant issuances and equity plan increases could lead to significant dilution for existing holders.
2026-04-07 23:40:33
Dermata Therapeutics, Inc. (DRMA) is soliciting proxies for its virtual 2026 Annual Meeting to be held on May 27, 2026. Stockholders will vote on key proposals including the election of three Class II directors, ratification of CBIZ as auditor, approval to issue shares underlying warrants equal to or exceeding 20% of outstanding common stock, repricing of warrants for 120,734 shares, and an increase in the 2021 Plan reserve to 402,214 shares. The Board recommends voting FOR all listed proposals, which are critical for the company's capital structure and continued ability to attract and retain talent through equity incentives.
2026-04-04 11:09:41
This article provides an analysis of Dermata Therapeutics Inc.'s (DRMA) financial performance, focusing on its profitability metrics and market position. It highlights the company's N/A gross, operating, and net margins, alongside a Return on Equity (ROE) of -194.20%, and compares these figures to competitors CPHI and XRTX. The analysis also touches on DRMA's market capitalization of $5.19M within the broader sector.
2026-04-03 10:11:22
Dermata Therapeutics (NASDAQ:DRMA) announced that the Australian Patent Office has accepted its patent application for a topical dermal filler program using its Bioneedle Delivery System. This marks a significant milestone for Dermata, expanding its intellectual property portfolio in the aesthetic market. The company, which is undergoing a strategic shift to direct-to-consumer skincare, plans to launch its first product utilizing this technology in mid-2026.
2026-04-02 23:39:36
Dermata Therapeutics, Inc. has announced that the Australian Patent Office has accepted its patent application for a topical dermal filler program utilizing its Bioneedle Delivery System, marking a significant step in expanding the delivery options for dermal fillers. This patent, if issued, would be the company's first specifically covering dermal fillers with this system, building on prior patents for botulinum toxin applications. Despite the company's strategic shift to direct-to-consumer skincare and a significant stock decline, analysts see substantial upside potential.
2026-04-02 12:40:38
Dermata (Nasdaq:DRMA) has received notice of acceptance from the Australian Patent Office for a patent application covering the topical delivery of dermal fillers using its Bioneedle Delivery System (BDS). This acceptance marks a significant milestone, potentially expanding the uses of dermal fillers beyond traditional injections and strengthening Dermata's global intellectual property portfolio. The company is also strategically shifting its commercial channel to direct sales to skincare professionals to enhance market access, with the patent expected to issue automatically in three months unless opposed.
